Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Revenue | $27.8M | $59.8M |
| Revenue growth | — | 115.1% |
| Gross profit | $362K | $24.2M |
| Gross margin | 1.3% | 40.5% |
| Operating income | -$85.1M | -$106M |
| Operating margin | -305.8% | -177.8% |
| Net income | -$94.1M | -$114M |
| Net margin | -338.4% | -190.3% |
| EPS (diluted) | -$5.07 | -$5.13 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$72.2M | -$77.6M |
| Capital expenditures | $12.2M | $22.9M |
| Free cash flow | -$84.5M | -$101M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $8.25M | $238M |
| Total assets | $45.9M | $296M |
| Total liabilities | $78.2M | $90.3M |
| Long-term debt | $42.5M | $41.1M |
| Shareholders' equity | -$209M | $205M |
| Retained earnings | -$406M | -$520M |
| Shares (wtd avg diluted) | 19.9M | 24.6M |
Every figure is extracted from KESTRA MEDICAL TECHNOLOGIES, LTD.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.